mRNA-1010

CAMBRIDGE, Mass., Aug. 5, 2026 Moderna, Inc. has received U.S. Food and Drug Administration (FDA) approval for mFLUSIVA® (mRNA-1010),...

CAMBRIDGE, Mass., June 20, 2026 Moderna, Inc. announced a major regulatory milestone for its investigational seasonal influenza vaccine mRNA-1010...

CAMBRIDGE, Mass., May 6, 2026 Moderna announced the publication of pivotal Phase 3 clinical safety and efficacy data for...